Geneva, March 20 -- International Clinical Trials Registry received information related to the study (KCT0011640) titled 'A Clinical Study of Standard Treatment Combined with Immune Cell Therapy (Immuncell-LC) in Patients with Newly Diagnosed Glioblastoma' on Feb. 24.
Study Type: Interventional Study
Study Design:
Primary Purpose : Treatment, Intervention Model : Single Group, Blinding/Masking : Open, Allocation : Not Applicable
Primary Sponsor: Yonsei University Health System, Severance Hospital
Condition:
Neoplasms
Intervention:
Biological/Vaccine, Non-Stem Cell : 1) Drug: Immuncell-LC(Activated T lymphocyte)
2) Dose: 1.0 x 10? to 2.0 x 10¹deg cells / 200 mL
3) Number of administrations: 11 (five administrations at 1-wee...